194 related articles for article (PubMed ID: 33646819)
1. In-Bore Versus Fusion MRI-Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting.
Prince M; Foster BR; Kaempf A; Liu JJ; Amling CL; Isharwal S; Chen Y; Coakley FV
AJR Am J Roentgenol; 2021 Nov; 217(5):1123-1130. PubMed ID: 33646819
[No Abstract] [Full Text] [Related]
2. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.
Costa DN; Goldberg K; Leon AD; Lotan Y; Xi Y; Aziz M; Freifeld Y; Margulis V; Raj G; Roehrborn CG; Hornberger B; Desai N; Bagrodia A; Francis F; Pedrosa I; Cadeddu JA
Eur Urol Oncol; 2019 Jul; 2(4):397-404. PubMed ID: 31277776
[TBL] [Abstract][Full Text] [Related]
3. The role of magnetic resonance imaging-guided biopsy for diagnosis of prostate cancer; comparison between FUSION and "IN-BORE" approaches.
D'Agostino D; Casablanca C; Mineo Bianchi F; Corsi P; Romagnoli D; Giampaoli M; Fiori C; Schiavina R; Brunocilla E; Artibani W; Porreca A
Minerva Urol Nephrol; 2021 Feb; 73(1):90-97. PubMed ID: 32456413
[TBL] [Abstract][Full Text] [Related]
4. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
6. PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.
Yilmaz EC; Lin Y; Belue MJ; Harmon SA; Phelps TE; Merriman KM; Hazen LA; Garcia C; Johnson L; Lay NS; Toubaji A; Merino MJ; Patel KR; Parnes HL; Law YM; Wood BJ; Gurram S; Choyke PL; Pinto PA; Turkbey B
AJR Am J Roentgenol; 2024 Jan; 222(1):e2329964. PubMed ID: 37729551
[No Abstract] [Full Text] [Related]
7. Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
Hanske J; Risse Y; Roghmann F; Pucheril D; Berg S; Tully KH; von Landenberg N; Wald J; Noldus J; Brock M
Prostate; 2022 Feb; 82(2):227-234. PubMed ID: 34734428
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial.
Klotz L; Chin J; Black PC; Finelli A; Anidjar M; Bladou F; Mercado A; Levental M; Ghai S; Chang SD; Milot L; Patel C; Kassam Z; Moore C; Kasivisvanathan V; Loblaw A; Kebabdjian M; Earle CC; Pond GR; Haider MA
JAMA Oncol; 2021 Apr; 7(4):534-542. PubMed ID: 33538782
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of Sampling PI-RADS 4-5 Index Lesions Alone by MRI-guided In-bore Biopsy in Biopsy-naive Patients Undergoing Radical Prostatectomy.
Kilic M; Vural M; Coskun B; Acar Ö; Saglican Y; Akpek S; Esen T
Eur Urol Focus; 2020 Mar; 6(2):249-254. PubMed ID: 31054811
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric MRI-ultrasonography software fusion prostate biopsy: initial results using a stereotactic robotic-assisted transperineal prostate biopsy platform comparing systematic vs targeted biopsy.
Lee AYM; Yang XY; Lee HJ; Law YM; Huang HH; Lau WKO; Lee LS; Ho HSS; Tay KJ; Cheng CWS; Yuen JSP; Chen K
BJU Int; 2020 Nov; 126(5):568-576. PubMed ID: 32438463
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.
Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ
World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396
[TBL] [Abstract][Full Text] [Related]
12. Prospective Evaluation of PI-RADS™ Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
Mehralivand S; Bednarova S; Shih JH; Mertan FV; Gaur S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
J Urol; 2017 Sep; 198(3):583-590. PubMed ID: 28373133
[TBL] [Abstract][Full Text] [Related]
13. Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Syed JS; Aneja S; Sprenkle PC; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 Feb; 210(2):347-357. PubMed ID: 29112469
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Yield of Incremental Biopsy Cores and Second Lesion Sampling for In-Gantry MRI-Guided Prostate Biopsy.
Seyfried N; Mahran A; Panda A; Obmann VC; Buzzy CA; Jiang Y; Wright KL; Nakamoto DA; Patel IJ; Conroy B; Ponsky L; Gulani V
AJR Am J Roentgenol; 2021 Oct; 217(4):908-918. PubMed ID: 33336582
[No Abstract] [Full Text] [Related]
15. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
[TBL] [Abstract][Full Text] [Related]
16. Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?
Leow JJ; Koh SH; Chow MW; Loke W; Salada R; Hong SK; Yeow Y; Lee CH; Tan CH; Tan TW
Asian J Androl; 2023; 25(1):43-49. PubMed ID: 35488666
[TBL] [Abstract][Full Text] [Related]
17. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
[TBL] [Abstract][Full Text] [Related]
18. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
[TBL] [Abstract][Full Text] [Related]
19. MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI.
Sheridan AD; Nath SK; Aneja S; Syed JS; Pahade J; Mathur M; Sprenkle P; Weinreb JC; Spektor M
AJR Am J Roentgenol; 2018 May; 210(5):W218-W225. PubMed ID: 29489409
[TBL] [Abstract][Full Text] [Related]
20. Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI-Transrectal US Fusion Prostate Biopsies.
Costa DN; Cai Q; Xi Y; Recchimuzzi DZ; Subramanian N; Bagrodia A; Rofsky NM; Roehrborn CG; Hornberger B; Shah RB; Goldberg K; Diaz de Leon A; Pedrosa I
Radiol Imaging Cancer; 2021 Mar; 3(2):e200123. PubMed ID: 33817652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
